CAMBRIDGE, Mass. — Abselion, a U.K.-based life sciences technology company focused on biomolecule quantification, has established a U.S. subsidiary at The Engine in Cambridge, expanding its presence in North America as adoption of its Amperia protein quantification platform grows internationally.
The new location will allow the company to work more closely with academic researchers, biotechnology companies and pharmaceutical developers across the United States who are engaged in biologics characterization and development.
The Cambridge site is located within The Engine, an incubator and accelerator created by the Massachusetts Institute of Technology to support “tough tech” startups working on complex scientific and engineering challenges. The facility provides laboratory infrastructure, collaboration opportunities and long-term company-building support for emerging technology firms.
Abselion said the U.S. subsidiary will provide an operational base to coordinate its growing activities in North America and support collaborations already underway with research groups in the region. The move also reflects the geographic distribution of the company’s customer base, which increasingly extends beyond the United Kingdom and Europe.
The company’s Amperia system is designed to simplify protein quantification workflows, enabling scientists to measure biomolecules more efficiently during biologics research and development.
“Our vision is to make high-quality quantification more accessible through closer international collaboration. Establishing a US subsidiary marks an important milestone in Abselion’s growth, strengthening our ability to operate across key life science markets globally while continuing to build on our strong scientific foundation,” said Dr. Ruizhi Wang, CEO and Founder, Abselion.
Wang said the United States represents a major center for biologics research and development, making a permanent presence in the country an important step for the company as adoption of its technology grows.
“The US represents a significant focus for advanced biologics research and development. A formal presence there demonstrates our commitment to supporting long-term adoption of our protein quantification systems and will allow our growing international team to work more closely with customers and partners as they explore and build workflows around our Amperia platform.”
